USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.
USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.
复制标题
USP22 通过其在乳腺癌中的去泛素酶活性积极调节 ERα 作用
DOI：
10.1038/s41418-020-0568-2
复制
发表时间：
2020
影响因子：
12.4
通讯作者：
Zhao Y
中科院分区：
文献类型：
--
作者：
Wang S;Zhong X;Wang C;Luo H;Lin L;Sun H;Sun G;Zeng K;Zou R;Liu W;Sun N;Song H;Liu W;Zhang Q;Liao Z;Teng X;Zhou T;Sun X;Zhao Y
雌激素受体α（ERα）是ERα阳性乳腺癌进展的关键因素。针对 ERα 信号传导的内分泌治疗是广泛使用的乳腺癌治疗策略之一。然而，大量患者变得难以治疗。 ERα协同调节因子的异常表达有利于乳腺癌的发展和内分泌抵抗的倾向。因此，有必要发现调节 ERα 作用的新型协同调节因子。在这里，我们证明，与良性组织相比，组蛋白去泛素酶 USP22 在乳腺癌样本中高表达，并且 USP22 的高表达与 BCa 样本中较差的总生存率显着相关。此外，USP22 与 ERα 结合，参与维持 ERα 的稳定性。 USP22 增强 ERα 诱导的反式激活。我们进一步提供了 USP22 与 ERα 靶基因的顺顺式调节元件一起招募的证据。即使在缺氧条件下以及用 ERα 拮抗剂治疗乳腺癌细胞时，USP22 也能促进细胞生长。重要的是，USP22 的去泛素化活性是其维持 ERα 稳定性的功能所必需的，从而增强 ERα 的作用并赋予乳腺癌内分泌抵抗。
Estrogen receptor α (ERα) is the crucial factor in ERα-positive breast cancer progression. Endocrine therapies targeting ERα signaling is one of the widely used therapeutic strategies for breast cancer. However, a large number of the patients become refractory to therapy. Abnormal expression of ERα co-regulator facilitates breast cancer development and tendency of endocrine resistance. Thus, it is necessary to discover the novel co-regulators modulating ERα action. Here, we demonstrate that histone deubiquitinase USP22 is highly expressed in breast cancer samples compared with that in the benign tissue, and high expression of USP22 was significantly associated with poorer overall survival in BCa samples. Moreover, USP22 associates with ERα to be involved in maintenance of ERα stability. USP22 enhances ERα-induced transactivation. We further provide the evidence that USP22 is recruited together with ERα tocis-regulatory elements of ERα target gene. USP22 promotes cell growth even under hypoxia condition and with the treatment of ERα antagonist in breast cancer cells. Importantly, the deubiquitination activity of USP22 is required for its functions on maintenance of ERα stability, thereby enhancing ERα action and conferring endocrine resistance in breast cancer.